These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1077 related articles for article (PubMed ID: 25464465)
1. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials. Sardar P; Chatterjee S; Lavie CJ; Giri JS; Ghosh J; Mukherjee D; Lip GY Int J Cardiol; 2015 Jan; 179():279-87. PubMed ID: 25464465 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Skjøth F; Larsen TB; Rasmussen LH; Lip GY Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485 [TBL] [Abstract][Full Text] [Related]
3. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis. Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161 [TBL] [Abstract][Full Text] [Related]
4. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495 [TBL] [Abstract][Full Text] [Related]
5. Bleeding and antidotes in new oral anticoagulants. Majeed A; Schulman S Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907 [TBL] [Abstract][Full Text] [Related]
6. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation]. Koziński M; Obońska K; Kubica A; Navarese EP; Kubica J Kardiol Pol; 2012; 70(10):1053-60. PubMed ID: 23080100 [No Abstract] [Full Text] [Related]
7. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. van der Hulle T; Kooiman J; den Exter PL; Dekkers OM; Klok FA; Huisman MV J Thromb Haemost; 2014; 12(3):320-8. PubMed ID: 24330006 [TBL] [Abstract][Full Text] [Related]
8. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. Kakkos SK; Kirkilesis GI; Tsolakis IA Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377 [TBL] [Abstract][Full Text] [Related]
9. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. Lip GY; Larsen TB; Skjøth F; Rasmussen LH J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324 [TBL] [Abstract][Full Text] [Related]
10. Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery. Harenberg J; Marx S; Dahl OE; Marder VJ; Schulze A; Wehling M; Weiss C Thromb Haemost; 2012 Nov; 108(5):903-12. PubMed ID: 23014668 [TBL] [Abstract][Full Text] [Related]
11. Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory. Blann AD Br J Biomed Sci; 2014; 71(4):158-67. PubMed ID: 25562993 [TBL] [Abstract][Full Text] [Related]
12. Novel oral anticoagulants--key messages for the angiologist. Haas S; Spannagl M; Schellong SM Vasa; 2012 May; 41(3):177-91. PubMed ID: 22565619 [TBL] [Abstract][Full Text] [Related]
13. New oral anticoagulant agents - general features and outcomes in subsets of patients. Schulman S Thromb Haemost; 2014 Apr; 111(4):575-82. PubMed ID: 24452881 [TBL] [Abstract][Full Text] [Related]
14. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548 [TBL] [Abstract][Full Text] [Related]
15. Perioperative management of patients on new oral anticoagulants. Lai A; Davidson N; Galloway SW; Thachil J Br J Surg; 2014 Jun; 101(7):742-9. PubMed ID: 24777590 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628 [TBL] [Abstract][Full Text] [Related]
17. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398 [TBL] [Abstract][Full Text] [Related]
18. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370 [TBL] [Abstract][Full Text] [Related]
19. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Mantha S; Ansell J Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145 [TBL] [Abstract][Full Text] [Related]
20. Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons. Verdecchia P; Angeli F; Lip GY; Reboldi G PLoS One; 2014; 9(6):e100478. PubMed ID: 24955573 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]